Garcia-Duran C, Grau F, Villacampa G, Oaknin A, et al. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. Int J Gynecol Cancer 2022 Apr 20. pii: ijgc-2022-003370.
PMID: 35444013